other material
confidence high
sentiment positive
materiality 0.65
Elicio presents ELI-002 7P Phase 1/2 trial design at ASCO GI; Phase 1A complete, Phase 2 enrolling
Elicio Therapeutics, Inc.
- Phase 1A completed with no dose-limiting toxicities; Phase 2 randomized 2:1 study enrolling PDAC patients.
- ELI-002 7P targets seven KRAS mutations driving 25% of solid tumors using AMP lymph node-targeting platform.
- First patient dosed in randomized Phase 2 cohort comparing ELI-002 7P to standard of care (observation).
- Previous 2-peptide formulation published in Nature Medicine showed tumor biomarker reduction and reduced risk of relapse/death.